28.23
-1.30 (-4.40%)
| Previous Close | 29.53 |
| Open | 29.31 |
| Volume | 384,938 |
| Avg. Volume (3M) | 711,754 |
| Market Cap | 1,620,026,496 |
| Price / Earnings (TTM) | 11.25 |
| Price / Earnings (Forward) | 8.31 |
| Price / Sales | 2.39 |
| Price / Book | 2.57 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 20.36% |
| Operating Margin (TTM) | 27.69% |
| Diluted EPS (TTM) | 2.51 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 85.90% |
| Total Debt/Equity (MRQ) | 27.52% |
| Current Ratio (MRQ) | 3.31 |
| Operating Cash Flow (TTM) | 219.82 M |
| Levered Free Cash Flow (TTM) | 143.91 M |
| Return on Assets (TTM) | 13.17% |
| Return on Equity (TTM) | 25.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Harmony Biosciences Holdings, I | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 0.20 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.61% |
| % Held by Institutions | 97.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Valor Management Llc | 31 Dec 2024 | 6,618,033 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 147.96%) | Buy |
| Median | 52.50 (85.97%) | |
| Low | 44.00 (Mizuho, 55.86%) | Buy |
| Average | 54.75 (93.94%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 32.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 10 Apr 2025 | 50.00 (77.12%) | Buy | 28.99 |
| 08 Apr 2025 | 50.00 (77.12%) | Buy | 28.13 | |
| HC Wainwright & Co. | 08 Apr 2025 | 70.00 (147.96%) | Buy | 28.13 |
| 27 Feb 2025 | 70.00 (147.96%) | Buy | 32.75 | |
| Mizuho | 18 Mar 2025 | 44.00 (55.86%) | Buy | 34.78 |
| 20 Feb 2025 | 42.00 (48.78%) | Buy | 34.89 | |
| Deutsche Bank | 11 Feb 2025 | 55.00 (94.83%) | Buy | 37.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |